CASI Pharmaceuticals (CASIF) Liabilities and Shareholders Equity (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $25.6 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 52.21% year-over-year to $25.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $81.4 million (down 53.6% YoY) and the FY2025 annual result came in at $25.6 million, down 52.21% from the prior year.
• Liabilities and Shareholders Equity climbed to $25.6 million in Q4 2025, from $24.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $138.3 million in Q4 2021 to a low of $40821.0 in Q1 2025.
• A 5-year average of $47.2 million and a median of $42.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 60757.01% in 2025, down 99.93% in 2025.
• Tracing CASIF's Liabilities and Shareholders Equity over 5 years: stood at $138.3 million in 2021, then slumped by 30.42% to $96.2 million in 2022, then slipped by 21.79% to $75.3 million in 2023, then retreated by 28.69% to $53.7 million in 2024, then plunged by 52.21% to $25.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $25.6 million (Q4 2025), $24.5 million (Q3 2025), and $31.2 million (Q2 2025), per Business Quant data.